Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.
about
Human genetics and genomics a decade after the release of the draft sequence of the human genomeSequencing and analysis of a South Asian-Indian personal genomeMedical implications of technical accuracy in genome sequencingIdentifying fusion transcripts using next generation sequencingTranslating cancer genomes and transcriptomes for precision oncologyPediatric AML: From Biology to Clinical ManagementTherapy-Related Myeloid NeoplasmsPromise of personalized omics to precision medicineGenomic sequencing in cancerAnnotating individual human genomesOvarian cancer biomarker discovery based on genomic approachesGenetic risk prediction in complex diseaseClinical tumor sequencing: opportunities and challenges for precision cancer medicineDevelopment and preliminary evaluation of an online educational video about whole-genome sequencing for research participants, patients, and the general publicASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?Getting personalized cancer genome analysis into the clinic: the challenges in bioinformaticsOrganizing knowledge to enable personalization of medicine in cancerThe origin and evolution of mutations in acute myeloid leukemiaEstimation of copy number alterations from exome sequencing data.Genomic sequencing: assessing the health care system, policy, and big-data implications.The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia.The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q).Systems biology: personalized medicine for the future?The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.Next-generation sequencing for cancer diagnostics: a practical perspective.Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagusPersonal genomes, quantitative dynamic omics and personalized medicineChallenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.Molecular pathogenesis of secondary acute promyelocytic leukemiaNGS catalog: A database of next generation sequencing studies in humans.Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.Oncolytic virotherapy for hematological malignancies.Translating cancer 'omics' to improved outcomes.Molecular genetics of AMLGenetics of melanomaBalancing personalized medicine and personalized careGenetic risk prediction for normal-karyotype acute myeloid leukemia using whole-exome sequencing.
P2860
Q21245451-F5A3C7D0-2658-46BC-B7D9-4545A377491AQ21266697-8FD16DF6-5D0E-4A46-BEDD-957E4BC5AA15Q23005220-AC709672-C52D-48E6-8BCA-7C58BADD4004Q26739900-A3F94C81-19D6-49C1-9DC4-A48F96D2B284Q26777081-87E66BFB-D5E1-45E2-9341-42B75894B313Q26799773-49657071-BA44-4989-85DB-A6D34DE1BE4DQ26799786-9ECC2197-F3F9-44FA-89C9-4350411D96C1Q26852592-000D7EB3-B427-4067-A921-E24CE92CEA6CQ26853507-A375FDCA-B46F-493F-843F-8D6CE796930BQ26999723-C17C4F15-BA52-4A11-AF44-8A628842481BQ27013687-8C1CA0C8-EFA1-42FA-B58A-7206E2C977ADQ27027720-3062EDB7-FDE1-406E-AB58-2FF0177ACB0AQ27027942-D4407B18-F579-4C23-B065-22A740A9D9D3Q27324190-AD0717FA-456F-4977-96E8-9F93A1D0336DQ27851909-B59C6BA1-1AEE-4D10-99E2-202A13B176E4Q28387115-4CE49A21-9400-4C19-898F-F8FA4BAB39E5Q28394818-7AA4B16C-AE17-4281-BF4B-4C2501AFC5BFQ28652806-B29A95CB-D493-463F-A149-6FB3E4A0DD7FQ29614630-2E6CA194-DB5A-40D8-B9F2-BC3B031638A4Q30584272-41A5D92F-781F-4B86-A2BF-2AB85E41CB6AQ30835712-8C5E52BD-863D-4B21-8CDA-CE3DFBFA62ADQ33717681-756CDEAE-2B1D-440E-9D5E-3C3944F94DE1Q33822153-4D545A58-6798-4CF0-B0CB-6149A66AA299Q33824947-39CAF2E6-1644-45DC-BB4B-AD374CA3DCE5Q34010735-CA61EAAF-C60D-4E6D-A673-96067F9DA30FQ34238930-276B46AA-2DB2-447E-AC3A-2C5AE35E0DB7Q34324683-83E20F7C-31E5-458F-98B0-2AEC9FBA91E0Q34547790-E82ED5D3-A871-4864-9B27-1D5D8FE1829DQ35195408-C88EF9A9-A92B-4A8F-ACD9-F6047E24EB90Q35213023-3A8ED488-9D37-4895-8D52-A803150CC4D5Q35486110-F4E04412-4E42-4143-B9DF-012156AD26DFQ35560260-D998164F-76A1-4A00-AC88-E64340A4B3D5Q35607189-7F827FEA-AD75-4C60-B851-A7F94FE31F24Q35636877-8A5A9EB9-5E43-4458-A592-AA0175CEFB29Q35692095-9EFD10F1-D63A-4A2B-AF55-75F5D2C16291Q35694365-493D4B59-75C3-4F5A-9310-8515D381BEF1Q36443062-282A5E07-5624-4454-BEDC-5AFDAFB2CE20Q36563659-B6464C69-31EC-4EF6-A13C-66B4E22EC826Q36644366-3E4646AE-1D7E-4265-9C51-27E72926D3C8Q36778481-2CBDAE6C-D806-46C0-8AD3-997E50002DC8
P2860
Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Identification of a novel TP53 ...... ient with therapy-related AML.
@ast
Identification of a novel TP53 ...... ient with therapy-related AML.
@en
type
label
Identification of a novel TP53 ...... ient with therapy-related AML.
@ast
Identification of a novel TP53 ...... ient with therapy-related AML.
@en
prefLabel
Identification of a novel TP53 ...... ient with therapy-related AML.
@ast
Identification of a novel TP53 ...... ient with therapy-related AML.
@en
P2093
P2860
P356
P1476
Identification of a novel TP53 ...... ient with therapy-related AML.
@en
P2093
Catrina C Fronick
Daniel C Koboldt
Daniel C Link
David J Dooling
Elaine R Mardis
Elizabeth L Appelbaum
Gerard P Zambetti
Heather Schmidt
Jacqueline E Payton
P2860
P304
P356
10.1001/JAMA.2011.473
P407
P577
2011-04-01T00:00:00Z